Group 2D: Novel Therapeutic, Triple Negative Breast Cancer

Thursday, Sept 15
2:00 pm – 3:30 pm Eastern Time (US/New York)

Poster #1:

The RNA Helicase Eif4a Is a Therapeutic Vulnerability In Metastatic Triple-Negative Breast Cancer

Poster author Na Zhao, Ph.D. will attend this session

Poster #2:

Combinatorial Chemo- and CSF-1R Antibody Targeted Therapy for the Treatment of Metastatic Triple Negative Breast Cancer

Poster author Diego Pedroza, Ph.D. will attend this session

Mentor: Julia Maués

Julia Maués was diagnosed with breast cancer in 2013 while pregnant. Following the birth of a healthy baby boy, Julia did tests she couldn’t do while pregnant and discovered the cancer had spread to her brain, liver, and bones. After many treatment setbacks, her cancer began to respond to treatment. Cancer is part of Julia’s life, but it doesn’t define her. Her goal is to make an impact while she is alive in the lives of others dealing with this disease. She has found meaning and purpose in working with patients and researchers to make cancer research more patient-centered, innovative, and inclusive.

Twitter: @itsnot_pink

Scientist: Veronique Debien, M.D.

Véronique Debien was trained as a medical oncologist in France, after moving to clinical research at Institut Jules Bordet, Brussels, Belgium. Involved in academia-promoted clinical trials, the patients’ input provided helpful suggestions for the clinical trial setting. Additionally, passionate about early phases, her goal is to make cancer knowledge accessible to a larger panel of patients, demystify clinical research in oncology and thus optimize clinician-patient collaboration.

Twitter: @veroniquedebien